What is SLE Phase III Lupuzor?

Category: Others

false

The SLE Phase III Lupuzor trial is a randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with Systemic Lupus Erythematosus. NCT02504645

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 1

Commonly reported side effects and conditions associated with SLE Phase III Lupuzor

Side effect Patients Percentage

Dosages

Based on patients currently using SLE Phase III Lupuzor

Dosage Patients Percentage
200 mcg monthly 1

Why patients stopped taking SLE Phase III Lupuzor

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 1
See 1 patient who's stopped using SLE Phase III Lupuzor

Duration

Currently using SLE Phase III Lupuzor

Duration Patients Percentage
2 - 5 years 1

Stopped using SLE Phase III Lupuzor

Duration Patients Percentage
6 months - 1 year 1
Adherence
Adherence Evaluations Percentage
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for SLE Phase III Lupuzor.